Marcin Trojanowski MD

Assistant Professor, Rheumatology

Clinic Director, Rheumatology

72 East Concord Street | (617) 638-4312
Marcin Trojanowski
Sections

Rheumatology

Centers

Arthritis & Autoimmune Diseases Research Center

Biography

Marcin Trojanowski, MD Clinical Assistant Professor of Medicine Director, Rheumatology Clinic Director, Scleroderma Program Section of Rheumatology Chobanian and Avedisian School of Medicine 72 East Concord Street, 5th floor Boston, MA 02118 Marcin Trojanowski, MD is a Clinical Assistant Professor of Medicine in Rheumatology at Chobanian and Avedisian School of Medicine. He has a decade of experience in treatment of systemic sclerosis as well as a passion for medical teaching.

Prior to his arrival at BUMC, Dr. Trojanowski was the head of the Scleroderma Clinic at UAB where he was the primary referral in the region. In this role he carved out a regional role in both systemic sclerosis as well as CTD-ILD. At BUMC, he has overseen an ever expanding role within the scleroderma clinic. He also serves as the Clinical Director of the Division of Rheumatology. Dr. Trojanowski has worked on many translational and epidemiological research studies such as the Genome Research in African American Scleroderma Patients (GRASP). He has participated in directly sponsored pharmaceutical research as the principle and sub investigator of dozens of drug trials in systemic sclerosis, systemic lupus and more recently COVID 19.

In education, Dr. Trojanowski excelled at UAB as a top ten teacher in the Department of Medicine as well as a leading teacher in the Division of Rheumatology. He was a member of the Strategic Committee on Education at UAB Department of Medicine. At Boston University, Dr. Trojanowski is the director of the rheumatology musculoskeletal module for the second-year medical students and has developed a multidisciplinary problem-based learning module for first year students.

Chief Clinical Interests: Systemic Sclerosis, Connective Tissue Diseases, and Lung Disease in Connective Tissue Disease

Other Positions

Education

MD, Medical University of South Carolina

Biology, BS, College of Charleston

Publications

Published on 12/19/2023

Lui JK, Cozzolino M, Winburn M, Trojanowski MA, Wiener RS, LaValley MP, Bujor AM, Gopal DM, Klings ES. Role of Left Ventricular Dysfunction in Systemic Sclerosis-Related Pulmonary Hypertension. Chest. 2023 Dec 19. PMID: 38128607.

Published on 11/13/2023

Lui JK, Gillmeyer KR, Sangani RA, Smyth RJ, Gopal DM, Trojanowski MA, Bujor AM, Soylemez Wiener R, LaValley MP, Klings ES. A Clinical Decision Tool for Risk Stratifying Patients with Systemic Sclerosis-Related Pulmonary Hypertension. Lung. 2023 Dec; 201(6):565-569. PMID: 37957388.

Published on 6/17/2023

Vakhshoorzadeh J, Lui JK, Sangani RA, Trojanowski MA, Bujor AM, LaValley MP, Klings ES. Emphysema and interstitial lung disease in systemic sclerosis-related pulmonary hypertension. Respir Med. 2023 Sep; 216:107333. PMID: 37336329.

Published on 4/25/2023

Pilitsi E, Kennamer B, Trepanowski N, Gonzalez R, Trojanowski M, Phillips T, Lam CS. Cannabis arteritis presenting with Raynaud's and digital ulcerations: a case-based review of a controversial thromboangiitis obliterans-like condition. Clin Rheumatol. 2023 Jul; 42(7):1981-1985. PMID: 37097526.

Published on 1/20/2023

Lui JK, Sangani RA, Gillmeyer KR, Vakhshoorzadeh J, Trojanowski MA, Bujor AM, Gopal DM, Wiener RS, LaValley MP, Klings ES. Correction to: Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis-Related Pulmonary Hypertension. Cardiovasc Drugs Ther. 2023 Jan 20. PMID: 36662449.

Published on 1/18/2023

Lui JK, Gillmeyer KR, Sangani RA, Smyth RJ, Gopal DM, Trojanowski MA, Bujor AM, Soylemez Wiener R, LaValley MP, Klings ES. A Multimodal Prediction Model for Diagnosing Pulmonary Hypertension in Systemic Sclerosis. Arthritis Care Res (Hoboken). 2023 Jul; 75(7):1462-1468. PMID: 35678779.

Published on 1/6/2023

Lui JK, Sangani RA, Gillmeyer KR, Vakhshoorzadeh J, Trojanowski MA, Bujor AM, Gopal DM, Wiener RS, LaValley MP, Klings ES. Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis-Related Pulmonary Hypertension. Cardiovasc Drugs Ther. 2023 Jan 06. PMID: 36607535.

Published on 10/1/2022

Sangani RA, Lui JK, Gillmeyer KR, Trojanowski MA, Bujor AM, LaValley MP, Klings ES. Clinical characteristics and outcomes in pulmonary manifestations of systemic sclerosis: Contribution from pulmonary hypertension and interstitial lung disease severity. Pulm Circ. 2022 Oct; 12(4):e12117. PMID: 36238967.

Published on 4/5/2022

Lui JK, Sangani RA, Chen CA, Bujor AM, Trojanowski MA, Gopal DM, LaValley MP, Soylemez Wiener R, Klings ES. Prognostic Value of Cardiac Axis Deviation in Systemic Sclerosis-Related Pulmonary Hypertension. Arthritis Care Res (Hoboken). 2022 Jul; 74(7):1219-1226. PMID: 34085410.

Published on 10/9/2020

Mazzotta C, Marden G, Farina A, Bujor A, Trojanowski MA, Trojanowska M. FLI1 and ERG protein degradation is regulated via Cathepsin B lysosomal pathway in human dermal microvascular endothelial cells. Microcirculation. 2021 01; 28(1):e12660. PMID: 32979864.

View full list of 14 publications.